Roflumilast
Back to searchMolecule Structure
Scientific Name
Roflumilast
Description of the Drug
Roflumilast is a selective phosphodiesterase-4 inhibitor indicated to decrease the risk of exacerbations in patients with severe chronic obstructive pulmonary disease (COPD) and to treat plaque psoriasis.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB01656
http://www.drugbank.ca/drugs/DB01656
Brand Name(s)
Daliresp, Daxas, Zoryve
Company Owner(s)
Micro Labs Ltd, Breckenridge Pharmaceutical Inc, Msn Laboratories Private Ltd, Astrazeneca Pharmaceuticals Lp, Hetero Labs Ltd Unit Iii, Mylan Pharmaceuticals Inc, Strides Pharma Global Pte Ltd, Zydus Pharmaceuticals Usa Inc, Prinston Pharmaceutical Inc, Torrent Pharmaceuticals Ltd
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Phosphodiesterase 4 | PROTEIN FAMILY | INHIBITOR | CHEMBL2093863 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL19158 | |
| PharmGKB | PA165948052 | |
| Human Metabolome Database | HMDB0257288 | |
| DrugBank | DB01656 | |
| PubChem: Thomson Pharma | 14879303 | |
| PubChem | 449193 | |
| LINCS | LSM-45821 | |
| Nikkaji | J1.365.537E | |
| PDBe | ROF | |
| BindingDB | 14774 | |
| EPA CompTox Dashboard | DTXSID8044123 | |
| DrugCentral | 3531 | |
| Brenda | 14446 | |
| ChemicalBook | CB7412688 | |
| Guide to Pharmacology | 6962 | |
| rxnorm | ROFLUMILAST | DALIRESP |
| PubChem: Drugs of the Future | 12014977 | |
| ChEBI | 47657 | |
| ZINC | ZINC000000592419 |
